Scheithauer BW, Erdogan S, Rodriguez FJ, Burger PC, Woodruff JM, Kros JM, et al
In addition to weight reduction, treatment with mazdutide was associated with significant improvements in metabolic parameters, including reductions in glycated hemoglobin (HbA1c), fasting plasma glucose, blood pressure, and lipid profiles in individuals with type 2 diabetes mellitus
What Brello Health Does Not Manage or Control This section outlines where Brello Healths platform role ends, based on how the company publicly describes its pricing, intake flow, clinician review, and pharmacy coordination
TM was a full-time employee of Novo Nordisk for the majority of manuscript development, and is a Novo Nordisk shareholder